J Korean Med Sci.  2024 Feb;39(5):e48. 10.3346/jkms.2024.39.e48.

Guillain–Barré Syndrome After COVID-19 Infection in Korea: A Case Series

• Ryoo N
• Son H
• Kim JH
• Bae DW
• An JY

• KMID: 2551978
• DOI: http://doi.org/10.3346/jkms.2024.39.e48

Abstract

Guillain–Barré syndrome (GBS) is an autoimmune-driven condition characterized by acute polyneuropathy, often emerging as a sequel to prior infections or vaccinations. This study presents the first reported cases of GBS emerging after the full recovery from coronavirus disease 2019 (COVID-19) infection in Korea. Despite experiencing mild acute COVID-19 symptoms, these patients faced substantial weakness attributed to GBS, significantly affecting their daily lives. The timely administration of intravenous immunoglobulin treatment halted the progression of symptoms, underscoring the critical importance of early intervention. These cases highlight the potential for neurological complications associated with COVID-19 and underscore the necessity for continuous monitoring and timely medical care.

Keyword

Guillain–Barré Syndrome; GBS; COVID-19; SARS-CoV-2; Peripheral Nervous System

Reference

1. Niazkar HR, Zibaee B, Nasimi A, Bahri N. The neurological manifestations of COVID-19: a review article. Neurol Sci. 2020; 41(7):1667–1671. PMID: 32483687.

2. Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet. 2016; 388(10045):717–727. PMID: 26948435.

3. Chmiela T, Rzepka M, Krzystanek E, Gorzkowska A. A 50-year-old patient with Guillain-Barré syndrome after COVID-19: a case report. Medicina (Kaunas). 2021; 57(8):775. PMID: 34440980.

4. Fragiel M, Miró Ò, Llorens P, Jiménez S, Piñera P, Burillo G, et al. Incidence, clinical, risk factors and outcomes of Guillain-Barré in Covid-19. Ann Neurol. 2021; 89(3):598–603. PMID: 33295021.

5. Zuberbühler P, Conti ME, León-Cejas L, Maximiliano-González F, Bonardo P, Miquelini A, et al. Guillain-Barre syndrome associated to COVID-19 infection: a review of published case reports. Rev Neurol. 2021; 72(6):203–212. PMID: 33710610.

6. Yiu AC, Hussain A, Okonkwo UA, Villacorta-Lyew R, McMahon MJ, Blattner M. Guillain-Barre syndrome associated with COVID-19 pneumonia-the first documented case in a U.S. military intensive care unit. Mil Med. 2023; 188(3-4):e852–e856. PMID: 33881526.

7. De Sanctis P, Doneddu PE, Viganò L, Selmi C, Nobile-Orazio E. Guillain-Barré syndrome associated with SARS-CoV-2 infection. A systematic review. Eur J Neurol. 2020; 27(11):2361–2370. PMID: 32757404.

8. Kim JY, Choe PG, Oh Y, Oh KJ, Kim J, Park SJ, et al. The first case of 2019 novel coronavirus pneumonia imported into Korea from Wuhan, China: implication for infection prevention and control measures. J Korean Med Sci. 2020; 35(5):e61. PMID: 32030925.

9. Pimentel V, Luchsinger VW, Carvalho GL, Alcará AM, Esper NB, Marinowic D, et al. Guillain-Barré syndrome associated with COVID-19: a systematic review. Brain Behav Immun Health. 2023; 28:100578. PMID: 36686624.

10. Ryoo N, Pyun JM, Baek MJ, Suh J, Kang MJ, Wang MJ, et al. Coping with dementia in the middle of the COVID-19 pandemic. J Korean Med Sci. 2020; 35(42):e383. PMID: 33140593.

11. Yachou Y, El Idrissi A, Belapasov V, Ait Benali S. Neuroinvasion, neurotropic, and neuroinflammatory events of SARS-CoV-2: understanding the neurological manifestations in COVID-19 patients. Neurol Sci. 2020; 41(10):2657–2669. PMID: 32725449.

12. Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020; 368(6490):473–474. PMID: 32303591.

13. Kang M, Seok HY. Finger drop-dominant variant of Guillain-Barre syndrome in a patient with COVID-19: a case report. J Korean Med Sci. 2022; 37(20):e160. PMID: 35607739.